Literature DB >> 7683505

Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica.

P F Piguet1, C Vesin, G E Grau, R C Thompson.   

Abstract

We explored the role of interleukin 1 (IL-1) in two models of pulmonary fibrosis (PF), elicited in mice by the intra-tracheal instillation of bleomycin or silica. In both models, administration of IL-1 receptor antagonist (IL-1ra) by an osmotic minipump implanted i.p., at a rate of 0.5 microgram/h, completely prevented the collagen deposition, as evaluated by the lung hydroxyproline content on day 15 after instillation. IL-1ra had little or no influence on the number of cells recovered from the broncho-alveolar lavage. Study of histological sections suggests that IL-1ra globally decreased the proportion of damaged lung and particularly in silica the formation of nodules with a rich content in collagen fibrils. IL-1ra was also effective in reducing the lung hydroxyproline content when given on day 25 after instillation of bleomycin or silica, indicating that it may reverse established PF. This study indicates that IL-1ra might be useful for the treatment of incipient or established pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683505     DOI: 10.1016/1043-4666(93)90024-y

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  55 in total

Review 1.  The role of oxidative stress in diseases caused by mineral dusts and fibres: current status and future of prophylaxis and treatment.

Authors:  M Gulumian
Journal:  Mol Cell Biochem       Date:  1999-06       Impact factor: 3.396

2.  Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis.

Authors:  M Kolb; P J Margetts; D C Anthony; F Pitossi; J Gauldie
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

3.  FTS reduces bleomycin-induced cytokine and chemokine production and inhibits pulmonary fibrosis in mice.

Authors:  S Yara; K Kawakami; N Kudeken; M Tohyama; K Teruya; T Chinen; A Awaya; A Saito
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

4.  Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.

Authors:  Michele Carbone; Haining Yang
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

5.  Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.

Authors:  Anagha A Divekar; Dinesh Khanna; Fereidoun Abtin; Paul Maranian; Rajeev Saggar; Rajan Saggar; Daniel E Furst; Ram Raj Singh
Journal:  Clin Immunol       Date:  2011-09-05       Impact factor: 3.969

6.  Pulmonary platelet trapping induced by bleomycin: correlation with fibrosis and involvement of the beta 2 integrins.

Authors:  P F Piguet; C Vesin
Journal:  Int J Exp Pathol       Date:  1994-10       Impact factor: 1.925

7.  IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice.

Authors:  Pamela Gasse; Caroline Mary; Isabelle Guenon; Nicolas Noulin; Sabine Charron; Silvia Schnyder-Candrian; Bruno Schnyder; Shizuo Akira; Valérie F J Quesniaux; Vincent Lagente; Bernhard Ryffel; Isabelle Couillin
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 8.  Host responses in tissue repair and fibrosis.

Authors:  Jeremy S Duffield; Mark Lupher; Victor J Thannickal; Thomas A Wynn
Journal:  Annu Rev Pathol       Date:  2012-10-22       Impact factor: 23.472

9.  Alternative strategies to manipulate fibrocyte involvement in the fibrotic tissue response: pharmacokinetic inhibition and the feasibility of directed-adipogenic differentiation.

Authors:  David W Baker; Yi-Ting Tsai; Hong Weng; Liping Tang
Journal:  Acta Biomater       Date:  2014-03-18       Impact factor: 8.947

Review 10.  Inflammasome and IL-1beta-mediated disorders.

Authors:  Hal M Hoffman; Alan A Wanderer
Journal:  Curr Allergy Asthma Rep       Date:  2010-07       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.